GPCR

🏥 Healthcare

Structure Therapeutics Inc.

Aggressive #488High RiskMixed 47F↑ 27pt

Market Cap

$4.7B

P/E Ratio

N/A

Rev Growth

0.0%

Sector avg: 161.5%

Earnings Growth

-36.7%

Profit Margin

0.0%

Sector avg: -3292.7%

Debt/Equity

0.92

Why This Score

GPCR scores 53.5 on the Aggressive profile, blending a fundamental score (55% weight, emphasizing growth and momentum (91% of fundamental weight)) with a machine-learning signal (45% weight) trained on 82 features across 30 years of data.

Strengths

Strong momentum (195%) — the market is rewarding this name.

Risk Factors

Momentum reversion risk: Extreme momentum (195%) increases mean-reversion probability. 5-point penalty applied.
Procyclicality: Late-cycle macro signals reduce confidence in extreme-momentum names. 2-point additional penalty.
Signal divergence: Fundamental and ML signals disagree by a significant margin, reducing confidence.

Net penalties of -12.4 points significantly impact the ranking. Without these adjustments, GPCR would rank considerably higher.

Score Breakdown

Overall Score53.5

Fundamental Score46.1

ML Score88.0

Score by Horizon

3 Month

6.5

6 Month

7.3

Primary

1 Year

7.7

Quality Assessment

Earnings Grade

Strong fundamentals, high earnings quality

Position Sizing

Suggested Allocation

11.5%

Confidence

medium

Score Composition Waterfall

How each component affects the final score

Backtested Scoring Levers (IC-calibrated from 30y ElasticNet)

Weinstein (12.1%)

100

Advancing

Sentiment (2.5%)

Positive

Analyst (6.4%)

Favorable

Tradability (post-hoc)

Grade A

Base

58.0

SHAP

+0.2

Factors

-0.5

Conviction

-0.2

Divergence

-4.0

Final

53.5

Positive adjustment

Negative adjustment

Base blend

Final score

Signal SegmentsComputed from ML features

Fundamental (Valuation, Quality, Growth)29.0

Technical (Momentum, Weinstein, Volatility)72.0

External (Sentiment, Analyst, Macro)91.0

Scores below 50 indicate weakness in that segment relative to the universe.

Data Quality

Score

Features

Confidence

Feature Coverage80%

Growth Estimates

Short-term

-14.9% to -7.8%

Medium-term

-20.1% to -10.0%

Long-term

-25.2% to -12.1%

ML Model Core Features100 trained inputs → ML Score: 88

These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.

Analyst Intelligence

Consensus Score75.0/100

Target Upside+66.6%

Coverage14 analysts

Market Sentiment

Sentiment Score90.0/100

News Volume1 articles

Technical Stage

Weinstein Stage2 — Advancing

12M Momentum+1.9%

6M Momentum+2.6%

Volatility+0.3%

Momentum & Technical

Momentum Acceleration-67.9%

Momentum ConsistencyStrong (0.74)

Relative Strength vs Sector+169.3%

Trend Strength (ADX Proxy)Strong (5.0)

Momentum Quality+1.283

Momentum BreadthBroad ✓

Macro Regime

Bull RegimeYes

High Vol RegimeNo

S&P 500 Return+25.0%

Yield Curve-0.1bp

Sector-Relative AnalysisIn-model features

Value Trap Signal

Low risk

Sector RevGr Rank

P43

Revenue growth vs Healthcare peers

Sector PE Rank

P24

Valuation vs Healthcare peers

Sector FCF Rank

P36

Free cash flow vs Healthcare peers

Growth Deviation

-0.0σ

Z-score vs sector median

Stagnation Flag

Not flagged

Analysis Signals

Scoring Factors

Fundamental score of 49 relative to sector peers49/100

Machine learning model ranks this stock at the 22th percentileP22

ML model weight reduced to 26% due to macro conditions: market in extended rally phase; yield curve inverted (recession indicator); late-cycle economic indicators detected26% ML weight

SHAP feature alignment: +0.2pt (features align with model priorities)—

Blend: 74% fund (49.2) + 26% ML (21.2) + SHAP(+0.2) = 42.1—

Factor quality: -0.5pt (multi-factor composite)—

Momentum mean-reversion: -2.9pt (195% 12m momentum)—

Divergence penalty: -1.1pt (fund 27pt higher)—

Risk Factors

Risk assessment: high. Strong momentum 195% → +12.0pt; Severe drawdown 34% → -1.2ptHigh

Sector Peer Comparison(Healthcare — Rank #62 of 344 stocks)

Stock	Score	P/E	Rev Growth	Margin	Mkt Cap
GPCRStructure Therapeutics Inc.	53.5	N/A	0.0%	0.0%	$4.7B
INCYIncyte Corporation	89.6	15.8	21.2%	25.0%	$20.1B
GMABGenmab A/S	85.5	13.1	22.8%	36.4%	$18.5B
CPRXCatalyst Pharmaceuticals, Inc.	82.2	13.7	23.5%	37.6%	$3.0B
VRTXVertex Pharmaceuticals Incorpor	78.0	32.1	8.9%	32.9%	$126.0B
ASNDAscendis Pharma A/S	75.7	16.6	98.0%	-31.7%	$13.3B
NBIXNeurocrine Biosciences, Inc.	74.7	26.5	21.4%	16.7%	$12.5B
ALKSAlkermes plc	74.6	16.5	-6.4%	23.9%	$5.5B
AMGNAmgen Inc.	73.8	26.0	10.0%	21.0%	$199.0B
ARGXargenx SE	73.6	35.1	78.6%	38.0%	$50.9B
HOLXHologic, Inc.	73.3	31.1	1.7%	13.8%	$16.8B
REGNRegeneron Pharmaceuticals, Inc.	72.7	19.4	1.0%	31.4%	$84.9B
ISRGIntuitive Surgical, Inc.	72.3	61.7	20.5%	28.4%	$172.5B
EXELExelixis, Inc.	71.9	15.1	7.0%	33.7%	$11.7B
KRYSKrystal Biotech, Inc.	71.0	41.4	473.0%	30.7%	$8.0B
HALOHalozyme Therapeutics, Inc.	70.2	16.8	22.4%	43.7%	$9.3B
Sector Average	37.1	252.3	161.5%	-3292.7%	—

Market Sentimentvia FMP

No analyst sentiment data available for GPCR.

Why This Stock

Healthcare

Tradability FilterGrade A — 91/100Score impact: -26.0pt

Volume

100

1.6M avg/day

Dollar Vol

100

$108M/day

Float

55M shares

Mkt Cap

$4.7B

Range

100

618% spread

Composite Liquidity Score91/100

FDCBA

Multi-Year Range Analysis

Sideways: 0/100

Year	Low	High	Range	Status
2023	$20.80	$75.02	113.2%	Wide
2024	$25.90	$62.74	83.1%	Wide
2025	$13.22	$94.90	151.1%	Wide

3-Year Range

151.1%

Narrow Years

0 / 3

Sideways Penalty

None

Free Float

95.1%

Outstanding Shares

58M

Bid-Ask Spread

618.0%

Institutional Tradable

Yes

Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.